Cellular Biomedicine Group competitors

Cellular Biomedicine Group Competitors include Replimune, Pharmacyclics, Cascadian Therapeutics and GlycoMimetics.
Add company...
Cellular Biomedicine Group
Cellular Biomedicine Group
Cellular Biomedicine Group is a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases.
Replimune
Replimune
Replimune Ltd. develops oncolytic immunotherapies for the treatment of cancer.
Pharmacyclics
Pharmacyclics
Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases.
Cascadian Therapeutics
Cascadian Therapeutics
Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company.
GlycoMimetics
GlycoMimetics
GlycoMimetics is a biopharmaceutical company designing and developing small molecule therapeutics to treat various cancers.
Founding Date
Founding Date
2009
Founding Date
2015
Founding Date
1991
Founding Date
2007
Founding Date
2003
Type
Type
Public
Type
Public
Type
Subsidiary
Type
Subsidiary
Type
Public
Tags
Locations
Locations
Cupertino, US HQ
Beijing, CN
Shanghai, CN
Hong Kong , HK
Locations
Milton, GB HQ
Woburn, US
Locations
Sunnyvale, US HQ
Shanghai, CN
Schaffhausen, CH
South San Francisco, US
Locations
Seattle, US HQ
Locations
Rockville, US HQ
Employees
Employees
12515% increase
Employees
N/A
Employees
N/A
Employees
N/A
Employees
405% decrease
Valuation ($)
Valuation ($)
360.6 m
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
484.9 m
Twitter followers
Twitter followers
154
Twitter followers
N/A
Twitter followers
840
Twitter followers
N/A
Twitter followers
N/A

Financial

Revenue (est.)
Revenue (est.)
$336.8k (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
$729.7m (FY, 2014)
Revenue (est.)
N/A
Revenue (est.)
N/A
Net income
Net income
($25.5m) (FY, 2017)
Net income
(£8.2m) (FY, 2018)
Net income
$86.1m (FY, 2014)
Net income
($56.9m) (FY, 2017)
Net income
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 30m
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 101.8m
For sources of this data, please see the company profileDownload Excel

View company profiles

Replimune
HQ
Milton, GB

Replimune Ltd. develops oncolytic immunotherapies for the treatment of cancer.

View company
Pharmacyclics
HQ
Sunnyvale, US

Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases.

View company
Cascadian Therapeutics
HQ
Seattle, US

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company.

View company
GlycoMimetics
HQ
Rockville, US
Employees
40↓ 5% decrease

GlycoMimetics is a biopharmaceutical company designing and developing small molecule therapeutics to treat various cancers.

View company